Nonalcoholic fatty liver disease (NAFLD) severely impairs the quality of life in patients and often leads to various liver complications. Recently, scientists at Gwangju Institute of Science and Technology designed a novel compound that can potentially treat NAFLD by targeting peripheral serotonin, which regulates lipid metabolism in the liver. They achieved this by structurally modifying an existing neurological drug such that it targets peripheral serotonin by minimizing brain penetration.
- Oncotarget: quantitative ultrasound radiomics in prediction of treatment response for breast cancer
- U of M trial shows hydroxychloroquine does not prevent COVID-19 in health care workers
- Covid-19 interventions can cut virus infections, severe outcomes, and healthcare needs
- Vanilla cultivation under trees promotes pest regulation
- NOAA report reveals condition of natural and cultural resources of Papahānaumokuākea